Intravenous or oral adjuvant CMF for node‐positive breast cancer

Geoffrey J. Lindeman, John Boyages*, Carla Driessen, Allan O. Langlands

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

To assess the optimal duration and method of administration of adjuvant cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) chemotherapy, 116 patients with positive axillary nodes after total mastectomy and axillary dissection were reviewed retrospectively. CMF was administered in three progressively shorter regimens, which consisted of oral CMF for either 12 or six cycles and intravenous (i.v.) CMF for six cycles. Median follow‐up for surviving patients was 62 months. The three groups were matched for major prognostic factors. There was no advantage in using more than six cycles of adjuvant CMF. Thre was an improved crude 3 year disease‐free survival (84 vs 65%, P= 0.05) and a trend towards improved overall survival (92 vs 85%, P= NS) in patients treated with six cycles of oral CMF compared with i.v. CMF. Survival rates were not significantly different beyond 3 years. Leucopenia and alopecia were more severe with oral CMF (P < 0.01), and compliance worse with oral CMF × 12 (P= 0.01). Since the data suggest that i.v. CMF is at least as equal as oral CMF a randomized controlled trial should be undertaken.

Original languageEnglish
Pages (from-to)556-562
Number of pages7
JournalAustralian and New Zealand Journal of Surgery
Volume62
Issue number7
DOIs
Publication statusPublished - 1992
Externally publishedYes

Fingerprint Dive into the research topics of 'Intravenous or oral adjuvant CMF for node‐positive breast cancer'. Together they form a unique fingerprint.

Cite this